CURx Pharmaceuticals is a specialty pharmaceutical company that licenses, develops and commercializes products that address unmet medical needs. Our focus is on searching for and licensing candidates for development based on sound scientific rationale; strong preclinical and clinical study results; defined regulatory pathway to approval; robust intellectual property protection; and defined market need. Our team cumulatively have over hundred years of experience in the biopharmaceutical industry; have worked for "big pharma” and smaller biotechnology companies; and have developed and marketed several block buster drugs.
Topiramate is a commonly prescribed antiepileptic drug which is also approved for prevention of migraine. Currently there are no options for patients on maintenance TPM therapy who are temporarily unable to take oral medications..... Read more
09/09/14: CURx Pharmaceuticals, Inc. licenses Captisol enable Lamotrigine from Ligand Pharmaceuticals
02/19/14: CURx Pharmaceuticals Announces License Agreement with Gilead Sciences
08/14/13: Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-EnabledTM Topiramate Injection
07/26/13: Ligand Receives Orphan Designation for Captisol-EnabledTM Topiramate Injection